- Home
- MDCX vs LSTA Comparison
MDCX vs LSTA Comparison
Compare MDCX & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | LSTA |
|---|---|---|
| Founded | 2008 | 1980 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | | Misc Health and Biotechnology Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 16.4M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | MDCX | LSTA |
|---|---|---|
| Price | $0.52 | $5.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $23.50 | $15.00 |
| AVG Volume (30 Days) | ★ 8.3M | 59.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.37 | $1.81 |
| 52 Week High | $8.90 | $5.07 |
Technical Indicators
Market Signals| Indicator | MDCX | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 31.96 | 71.48 |
| Support Level | $0.37 | $2.31 |
| Resistance Level | $1.43 | N/A |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 11.47 | 96.15 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.